1. Is RAP diagnostic or a screening tool? The presentation slides/company communication pump up diagnostic, then have a size 8 font disclaimer that its actually a screening tool......Clearly diagnostic space worth many multiples vs a screening tool. If it is actually just a screening tool, then ASIC needs to act, and punish the clearly misleading announcements and marketing of company
2. Current regulation prevents diagnosis of pneumonia without an xray - So RAP either needs a way to change this regulation or it will be illegal to sell their product as a diagnostic tool
3. Why are the "Aussie studies" only published in the lowest level journals that basically anyone and anything gets accepted into. Also what effort is made to address the fact that the US studies failed, and how does the company expect to be any chance of achieving FDA approval with these failed US studies.
That should do for now - Pretty straight forward questions really. If you cant answer, may be time to switch back over and hang out with your friends in the rescrap (sorry Resapp) forum.
RSH Price at posting:
9.9¢ Sentiment: Buy Disclosure: Held
